Abstract:Introduction Increasing evidence has shown that trefoil factor 3 (TFF3) is increased in expression in various cancers and promotes cancer progression. Elevated TFF3 levels have been reported in lung cancer patients. TFF3, which is expressed in the vast majority of lung adenocarcinomas (ADC), has also been proposed as a novel biomarker to distinguish between lung ADC and squamous-cell carcinoma (SCC). Herein, we investigated the oncogenic functions of TFF3 and explored the potential of therapeutic TFF3 inhibition in NSCLC. Material and methods The function of TFF3 in lung ADC was investigated by either forced or depleted expression of TFF3 in H1299 and H1975 cell lines. Cell functional assays performed include total cell count, PI-Annexin V apoptosis assay, cell cycle analysis, soft agar colony formation, 3Dgrowth in Matrigel, wound healing and transwell migration and invasion assays. A novel small molecule TFF3 inhibitor, AMPC, has been developed in and was used to examine the functional effects of TFF3 inhibition in the lung ADC cells, both as a single agent and in combination with MEK1/2 inhibitors. The paracrine effect of local TFF3 production by lung ADC cells on non-TFF3 expressing lung SCC cells was examined using co-culture assays. Results and discussions The forced expression of TFF3 enhanced cell proliferation and survival, increased anchorage-independent growth, and promoted cell migration and invasion in lung ADC cells. In contrast, the siRNA-mediated depletion of TFF3 expression decreased the oncogenicity of these cells. Consistently, the inhibition of TFF3 by AMPC resulted in markedly decreased cell survival, proliferation, 3D growth and foci formation of lung ADC cells. Expression of the proto-oncogene ARAF was increased by forced expression of TFF3 in lung ADC cells, with consequent increased activation of downstream MEK1/2 and ERK1/2. This TFF3-mediated activation of the MAPK/ERK pathway was required for TFF3-stimulated 3D-growth of lung ADC cells. Moreover, the combination of MEK1/2 inhibitors with AMPC exhibited synergistic inhibitory effects in lung ADC cells. In addition, we demonstrated that the local secretion of TFF3 from lung ADC cells exerts paracrine effects on lung SCC cells, which is relevant in the adenosquamous carcinoma (ASC) subtype of NSCLC. Conclusion TFF3 is a crucial oncogene in NSCLC progression.The therapeutic inhibition of TFF3 alone or in combination with conventional MEK1/2 inhibitors are potential strategies in the treatment of NSCLC.

Oncogenic tRNA‐derived fragment tRF‐Leu‐CAG promotes tumorigenesis of lung cancer via targeting TCEA3 and increasing autophagy

TIGAR promotes malignant proliferation of NSCLC by modulating deoxynucleotide anabolism via a YBX1-RRM2B axis

The tRNA‐derived fragment 5'tRF‐Gly promotes the development of hepatocellular carcinoma via direct targeting of CEACAM1

The role of tRF-Val-CAC-010 in lung adenocarcinoma: implications for tumorigenesis and metastasis

Transfer RNA-derived Fragment 5'Trf-Gly Promotes the Development of Hepatocellular Carcinoma by Direct Targeting of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1.

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Global Identification and Characterization of Trna-Derived RNA Fragment Landscapes Across Human Cancers

Trna-Derived Fragments: Mechanism of Gene Regulation and Clinical Application in Lung Cancer.

Nrf2 Promotes Progression of Non-Small Cell Lung Cancer Through Activating Autophagy

Long Noncoding RNA CTD-2245E15.3 Promotes Anabolic Enzymes ACC1 and PC to Support Non–Small Cell Lung Cancer Growth

Pan-cancer Trna-Derived Fragment CAT1 Coordinates RBPMS to Stabilize NOTCH2 Mrna to Promote Tumorigenesis.

tRNA-derived RNA fragment, tRF-18-8R6546D2, promotes pancreatic adenocarcinoma progression by directly targeting ASCL2

LTF Induces Radioresistance by Promoting Autophagy and Forms an AMPK/SP2/NEAT1/miR-214-5p Feedback Loop in Lung Squamous Cell Carcinoma

FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer

TGF-(3-induced Lncrna TBUR1 Promotes EMT and Metastasis in Lung Adenocarcinoma Via Hnrnpc-Mediated GRB2 Mrna Stabilization

METTL3‑mediated M6a Modification of Bcl‑2 Mrna Promotes Non‑small Cell Lung Cancer Progression

GPRC5A promotes paclitaxel resistance and glucose content in NSCLC

Association Between the Atf3 Gene and Non-Small Cell Lung Cancer

PO-001 Therapeutic Inhibition of Trefoil Factor 3(TFF3) Decrease Oncogenic Behaviour in Non-Small Cell Lung Cancer (NSCLC)

P2.15-009 Linc00173 Modulates Chemoresistance of Small Cell Lung Cancer by Functioning As a Competing Endogenous RNA to Regulate Etk Expression

tRF-29-79 regulates lung adenocarcinoma progression through mediating glutamine transporter SLC1A5